Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Bellicum Pharmaceuticals (Nasdaq: BLCM) announced that CEO Rick Fair will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bellicum Pharmaceuticals (Nasdaq: BLCM) announced that CEO Rick Fair will participate in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded presentation will be available on-demand from September 12, 2022, at 7 a.m. ET for 90 days. The company focuses on controllable cellular immunotherapies for cancers, with its GoCAR-T® product candidates, BPX-601 and BPX-603, designed to enhance CAR-T cell therapy effectiveness. More details can be found on their official website.
Details
News Market Reaction – BLCM
The recorded move for BLCM in the trading session of this news was -10.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.
Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.